Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Bromocriptine mesylate
Drug ID BADD_D00305
Description Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It is indicated for the management of signs and symptoms of Parkinsonian Syndrome. Bromocriptine also inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. It also causes sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly. Bromocriptine has been associated with pulmonary fibrosis.
Indications and Usage For the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodopa in advanced cases with motor complications. Bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome.
Marketing Status approved; investigational
ATC Code G02CB01; N04BC01
DrugBank ID DB01200
KEGG ID D00780
MeSH ID D001971
PubChem ID 31100
TTD Drug ID D06YFA
NDC Product Code 0574-0106; 55486-1561; 30698-201; 0781-5325; 0378-7096; 68012-258; 60687-286; 65841-654; 73212-035; 51927-2274; 30698-202; 68382-110
UNII FFP983J3OD
Synonyms Bromocriptine | 2-Bromo-alpha-ergokryptine | 2 Bromo alpha ergokryptine | Bromocryptin | 2-Bromoergokryptine | 2 Bromoergokryptine | Bromocriptin | 2-Bromoergocryptine | 2 Bromoergocryptine | 2-Bromo-alpha-ergocryptine | 2 Bromo alpha ergocryptine | CB-154 | CB 154 | CB154 | Parlodel | 2-Bromoergocryptine Mesylate | 2 Bromoergocryptine Mesylate | Mesylate, 2-Bromoergocryptine | Bromocriptine Mesylate | Mesylate, Bromocriptine | 2-Bromoergocryptine Methanesulfonate | 2 Bromoergocryptine Methanesulfonate | Methanesulfonate, 2-Bromoergocryptine
Chemical Information
Molecular Formula C33H44BrN5O8S
CAS Registry Number 22260-51-1
SMILES CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C 4)Br)C)O.CS(=O)(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urinary retention20.02.02.011--
Urticaria10.01.06.001; 23.04.02.001--
Vasculitis10.02.02.006; 24.12.04.027--
Vasospasm24.04.02.002---
Ventricular tachycardia02.03.04.010--
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred06.02.06.007; 17.17.01.010--
Visual impairment06.02.10.013---
Vomiting07.01.07.003--
Sudden onset of sleep17.15.04.003---
Acute coronary syndrome02.02.02.015; 24.04.04.011---
Ocular discomfort06.08.03.008---
Temperature intolerance08.01.09.022---
Disturbance in sexual arousal19.08.04.003---
Angiopathy24.03.02.007---
Neurological symptom17.02.05.010---
Cardiac disorder02.11.01.003---
Connective tissue disorder10.04.04.026; 15.06.01.006---
Impulse-control disorder19.18.01.002---
Mediastinal disorder22.09.03.001---
Mental disorder19.07.01.002---
Cardiac valve disease02.07.02.001---
Decreased appetite08.01.09.028; 14.03.01.005--
Gastrointestinal ulcer07.04.04.002---
Inner ear disorder04.04.02.002---
Parkinson's disease17.01.05.010---
Neoplasm recurrence16.16.02.004---
Psychotic disorder19.03.01.002--
Hypersexuality19.08.03.005---
Type 2 diabetes mellitus05.06.01.003; 14.06.01.003---
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages